Literature DB >> 27552387

Bilateral Vestibulopathy Aggravates Balance and Gait Disturbances in Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis: A Case Report.

Roeland B van Leeuwen1, Bart W Smits, Richard J Rodenburg, Baziel G van Engelen.   

Abstract

In patients with a triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO), the presenting features are mainly ataxia or ptosis. SANDO patients often have impaired balance and gait, which is not surprising considering the combination of sensory ataxic neuropathy, and additional symptoms like cerebellar ataxia and limb girdle weakness. We describe a SANDO patient who noticed an increasingly impaired balance and gait, without any dizziness. Neurological investigation revealed an external ophthalmeplegia and a cerebellar ataxia; the head impulse test was not reliable because of eye movement disorders. The caloric reflex tests showed lack of responses on both sides, compatible with severe bilateral vestibulopathy. Making the diagnosis of bilateral vestibulopathy in SANDO patients may have implications for the management of the patient, because specific vestibular rehabilitation can improve gaze and postural stability.

Entities:  

Mesh:

Year:  2016        PMID: 27552387     DOI: 10.1097/CND.0000000000000126

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  2 in total

1.  Uncovering bilateral vestibulopathy in patients with SANDO syndrome caused by mutations in POLG gene: a case series.

Authors:  Alexandra Belyakova-Bodina; Mikhail Ratanov; Erich Schneider; Yury Seliverstov; Evgenii Nuzhnyi; Sergey Klyushnikov; Amayak Broutian
Journal:  J Neurol       Date:  2021-06-12       Impact factor: 4.849

2.  Full Spectrum of Reported Symptoms of Bilateral Vestibulopathy Needs Further Investigation-A Systematic Review.

Authors:  Florence Lucieer; Stijn Duijn; Vincent Van Rompaey; Angelica Pérez Fornos; Nils Guinand; Jean Philippe Guyot; Herman Kingma; Raymond van de Berg
Journal:  Front Neurol       Date:  2018-06-04       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.